An Active Surveillance Study to Monitor the Real-World Safety of Ritlecitinib Among Patients with Alopecia Areata in Denmark, France, and Sweden

21/05/2025
02/11/2026
EU PAS number:
EUPAS1000000512
Study
Planned
Study identification

EU PAS number

EUPAS1000000512

Study ID

1000000512

Official title and acronym

An Active Surveillance Study to Monitor the Real-World Safety of Ritlecitinib Among Patients with Alopecia Areata in Denmark, France, and Sweden

DARWIN EU® study

No

Study countries

Denmark
France
Sweden

Study description

This is a non-interventional study (NIS) based on secondary routinely collected electronic healthcare data from routine clinical practice aiming to actively monitor the safety events of interest following exposure to ritlecitinib, baricitinib, upadacitinib or other approved systemic treatments for Alopecia Areata (AA) following the EU approval of ritlecitinib.

Study status

Planned
Research institutions and networks

Institutions

Pfizer
First published:
01/02/2024
Institution

Contact details

Cherise Wong

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Pfizer 100%
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)